CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤中脑与肝脏葡萄糖活性比值及疾病活动度
英文原题：The ratio of brain to liver glucose activity and disease activity in multiple myeloma.
查看英文原题
The ratio of brain to liver glucose activity and disease activity in multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肿瘤细胞代谢活性的改变是癌症的标志之一。癌细胞表现出Warburg效应，即高葡萄糖消耗以满足其能量需求。这为使用18 F-2-脱氧-D-葡萄糖进行正电子发射断层扫描成像以评估肿瘤负荷和治疗反应提供了基础。我们假设代谢活跃的肿瘤可能与大脑竞争葡萄糖摄取，并评估了不同缓解和复发状态的多发性骨髓瘤患者大脑和肝脏的葡萄糖摄取。脑与肝葡萄糖活性比值（B2LR）反映了骨髓瘤的疾病活动，预测髓外疾病的存在，并且还能预测对CAR-T 细胞治疗的短期反应。与B2LR值持续较高的患者相比，B2LR低的患者生存期也更差。我们简单的代谢比值在骨髓瘤和其他肿瘤中具有预后意义。
展开英文摘要原文
Changes in metabolic activity in tumor cells is one of the hallmarks of cancer. Cancer cells exhibit the Warburg effect with high glucose consumption for their energy needs. This provides the basis for imaging using 18 F-2-deoxy-D-glucose for positron emission tomography to assess tumor burden and response to therapy.
We postulated that metabolically active tumors may compete with the brain for glucose uptake and evaluated glucose uptake in the brain and liver in patients with multiple myeloma in various states of response and relapse.
The ratio of brain to liver glucose activity (B2LR) mirrors disease activity in myeloma, predicts the presence of extramedullary disease and is also predictive of a short response to chimeric antigen receptor T cell therapy. Patients with a low B2LR also have an inferior survival compared to patients with persistently higher B2LR values.
Our simple metabolic ratio has prognostic implications in myeloma and other tumors.
论文信息
- 作者
- Dingli S、Rothweiler P、Binder M、Cook J、Gertz MA、Hayman S、Kapoor P、Kourelis T
- 第一作者单位
- Earl E. Bakken Medical Devices Center, Department of Mechanical Engineering, College of Science and Engineering, University of Minnesota, Twin Cities, MN, USA.United States
- 通讯作者单位
- Division of Hematology and Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. dingli.david@mayo.edu.United States
- 期刊
- Blood cancer journal2025 May 7
- 原文标识
- PubMed 40335455 · DOI 10.1038/s41408-025-01280-2
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →